Efficacy Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions

In the human body, blood cells are produced in a factory called the bone marrow. Usually, this factory operates with strict instructions, ensuring that red cells, white cells, and platelets are made in the right amounts and with the right functions. Sometimes, however, a glitch occurs in the genetic blueprint of a stem cell—the master cell that gives rise to all blood types. This glitch can cause the factory to go into overdrive, producing too many of a specific type of white blood cell, or it can cause the cells to become immature and cancerous. One such rare and confusing group of disorders involves the overproduction of eosinophils, a type of white blood cell that normally fights parasites and allergies. When these cells appear in large numbers alongside a specific type of broken genetic instruction, doctors call the condition a myeloid or lymphoid neoplasm with eosinophilia. The "broken instruction" in these cases is often a fusion of two genes that creates a switch stuck in the "on" position, driving the cancer to grow. Because these diseases are so rare and can look like many other blood cancers, they are frequently misdiagnosed, leaving patients without the correct treatment for too long.

A team of researchers at Hebei Yanda Lu Daopei Hospital in China set out to understand these elusive conditions better by looking back at the medical records of thirteen patients diagnosed between 2013 and 2024. These patients had a specific type of cancer where a gene fusion acted as a permanent accelerator for cell growth. The researchers wanted to see how these patients were initially identified, what specific genetic errors they carried, and whether a major medical procedure known as an allogeneic hematopoietic stem cell transplant could offer a cure. This transplant involves replacing a patient's entire blood-making system with healthy stem cells from a donor, essentially rebooting the body's blood factory. The study focused on a diverse group of patients, ranging in age from six to fifty-nine years, with a median age of forty-two. Most were men, and their initial diagnoses were a mix of different blood cancers, including acute lymphoblastic leukemia, myeloproliferative neoplasms, and myelodysplastic syndromes. This variety highlighted how easily the disease can be mistaken for more common conditions.

The researchers found that the genetic errors driving these cancers were not all the same. In six patients, the problem lay in a gene called FGFR1; in three others, it was PDGFRA; two had PDGFRB; and one each had JAK2 and ETV6::ABL1. While high levels of eosinophils are a hallmark of this disease, the study showed that this symptom was not always present. Only eight of the thirteen patients had elevated eosinophils at the time of diagnosis, meaning that relying solely on this blood count could cause doctors to miss the diagnosis in nearly half of the cases. Furthermore, the disease did not always stay confined to the bone marrow. Five patients had the cancer spread to other parts of the body, such as lymph nodes or the central nervous system, making the condition even more complex to treat. The study emphasized that because the disease can look like so many different things, doctors need to use advanced genetic testing to find the specific broken gene switch, rather than just treating the symptoms.

When it came to treatment, the researchers observed a clear divide in outcomes based on whether patients received a stem cell transplant. Six patients underwent the transplant procedure. Before the surgery, some had received targeted drugs designed to turn off the specific gene switch driving their cancer, while others received standard chemotherapy. After the transplant, five of these six patients were still alive when the study concluded in September 2025, representing a five-year survival rate of 83.3 percent. One patient in this group unfortunately passed away due to a severe immune reaction where the new donor cells attacked the patient's body, a known risk of this procedure. In contrast, the seven patients who did not receive a transplant had a much harder time. Four of them died because their original disease returned or worsened, and the other three were lost to follow-up. The study noted that while drugs targeting the gene fusions could help control the disease for a while, they were rarely a permanent cure on their own, except in one specific subtype involving the PDGFRA gene.

The findings suggest that for most patients with this rare and aggressive group of blood cancers, the only path to long-term survival is the stem cell transplant. The researchers pointed out that the disease is highly variable; some genetic types, like those involving FGFR1, tend to be more aggressive and often present as acute leukemia, while others might linger in a slower phase before becoming dangerous. Because the disease can hide behind a mask of other blood disorders, the study argues that doctors must be vigilant. They recommend that whenever a patient presents with signs of a blood cancer that does not respond well to standard treatment, or when eosinophils are present without a clear cause, doctors should immediately look for these specific gene fusions. Once identified, the strategy should be to use targeted drugs to bring the disease under control as a bridge to a transplant, rather than relying on the drugs alone. The study concludes that while these cancers are difficult to diagnose and treat, identifying the specific genetic cause and moving quickly to a transplant offers the best chance for a patient to survive and thrive.